Optimizing safety mechanisms to mitigate HSPC toxicity and integrating donor or off-the-shelf NK cell platforms will be critical for translating FLT3-targeted CAR therapies into durable and safe treatment options for high-risk AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.